These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28853677)

  • 1. Reasons for switching ART: Comparison of data collected in 2012-2013 and 2014-2015 in Florence, Italy.
    Fusco FM; Burla MC; Degli Esposti A; Pierotti P; Rabatti L; Vichi F
    Int J STD AIDS; 2018 Mar; 29(4):392-395. PubMed ID: 28853677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure.
    Khaykin P; Postel N; Reeb I; Staszewski S
    Eur J Med Res; 2008 Apr; 13(4):169-72. PubMed ID: 18504172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.
    Hawkins C; Hertzmark E; Spiegelman D; Muya A; Ulenga N; Kim S; Khudyakov P; Christian B; Sando D; Aris E; Fawzi W
    J Antimicrob Chemother; 2017 Jul; 72(7):2060-2068. PubMed ID: 28387836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.
    Hanna DB; Hessol NA; Golub ET; Cocohoba JM; Cohen MH; Levine AM; Wilson TE; Young M; Anastos K; Kaplan RC
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):587-96. PubMed ID: 24326606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
    Bernaud C; Khatchatourian L; Rodallec A; Hall N; Perre P; Morrier M; Pineau S; Jovelin T; André-Garnier E; Raffi F; Allavena C
    Infect Dis (Lond); 2016 Oct; 48(10):754-9. PubMed ID: 27389932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients.
    Hart E; Curtis H; Wilkins E; Johnson M
    HIV Med; 2007 Apr; 8(3):186-91. PubMed ID: 17461863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch strategies in antiretroviral therapy regimens.
    Van den Eynde E; Podzamczer D
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1055-74. PubMed ID: 25075752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
    AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy in treatment-naïve patients with HIV infection.
    Camacho R; Teófilo E
    Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S3-11. PubMed ID: 22156777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
    Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
    Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antiretroviral regimen switches on adherence.
    Miller LG; Golin CE; Hays RD; Liu H; Beck CK; Kaplan AH; Wenger NS
    HIV Clin Trials; 2002; 3(5):355-60. PubMed ID: 12407484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A decade of antiretroviral therapy: a profile of patients with 10 years of highly effective triple therapy].
    Wilson G; Wolff M
    Rev Chilena Infectol; 2012 Jun; 29(3):337-43. PubMed ID: 23096476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.